No connection

Search Results

Corporate Score 55 Bullish

Novo Nordisk CEO says weight-loss drug boom has barely begun

Apr 05, 2026 12:27 UTC
NOVO.CO, MRK, ^GSPC
Medium term

Novo Nordisk CEO says weight-loss drug boom has barely begun.

  • Novo Nordisk CEO highlights the early stage of the weight-loss drug market.
  • Potential for continued growth in the sector.

hapabapa/iStock Editorial via Getty Images Pharmaceutical companies have only begun to tap the potential demand for obesity treatments, and expanding access should be a top priority, said Mike Doustdar, the head of Novo Nordisk (NVO), the maker of Wegovy and Ozempic. Speaking in an interview

Sign up free to read the full analysis

Create a free account to unlock full AI-curated market articles, personalized alerts, and more.

Create Free Account Already have an account? Sign In
Share this article

Stay Ahead of the Markets

Join thousands of traders using AI-powered market intelligence. Get personalized insights, real-time alerts, and advanced analysis tools.

Get Started Free View Plans
Features Terminal AI Assistant Analysis Market News Pricing
Start Trading with AI Already have an account? Sign In
Home
Terminal
AI
Markets
Profile